New Ray Medicine International Holding (HKSE:06108) Debt-to-Equity : 0.00 (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is New Ray Medicine International Holding Debt-to-Equity?

New Ray Medicine International Holding's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$0.29 Mil. New Ray Medicine International Holding's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$0.00 Mil. New Ray Medicine International Holding's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$480.25 Mil. New Ray Medicine International Holding's debt to equity for the quarter that ended in Dec. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for New Ray Medicine International Holding's Debt-to-Equity or its related term are showing as below:

During the past 12 years, the highest Debt-to-Equity Ratio of New Ray Medicine International Holding was 0.04. The lowest was 0.00. And the median was 0.00.

HKSE:06108's Debt-to-Equity is not ranked ^*
in the Healthcare Providers & Services industry.
Industry Median: 0.48
* Ranked among companies with meaningful Debt-to-Equity only.

New Ray Medicine International Holding Debt-to-Equity Historical Data

The historical data trend for New Ray Medicine International Holding's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

New Ray Medicine International Holding Debt-to-Equity Chart

New Ray Medicine International Holding Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.02

New Ray Medicine International Holding Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.02	-	-	-	-

Competitive Comparison of New Ray Medicine International Holding's Debt-to-Equity

For the Pharmaceutical Retailers subindustry, New Ray Medicine International Holding's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

New Ray Medicine International Holding's Debt-to-Equity Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, New Ray Medicine International Holding's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where New Ray Medicine International Holding's Debt-to-Equity falls into.

New Ray Medicine International Holding Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

New Ray Medicine International Holding's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.288	+	0)	/	480.253
	=	0.00

New Ray Medicine International Holding's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.288	+	0)	/	480.253
	=	0.00

New Ray Medicine International Holding (HKSE:06108) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

New Ray Medicine International Holding Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of New Ray Medicine International Holding's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

New Ray Medicine International Holding (HKSE:06108) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » New Ray Medicine International Holding Ltd (HKSE:06108) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

19 Dangui Road, B-C, 37th Floor, Dikai International Center, Hangzhou, CHN

Website

http://www.newraymedicine.com

New Ray Medicine International Holding Ltd is engaged in the trading of pharmaceutical products in the People's Republic of China. The company's segments include Distribution and trading of pharmaceutical products and Provision of marketing and promotion services. Distribution and trading of pharmaceutical products consist of Injection drugs, Capsules and Granule drugs, Tablet drugs and Other Drugs. It generates a majority of its revenue from the distribution of Injection Drugs.

Executives

Dai Xiaosong
Eagle Amber Holdings Limited
Chu Xueping	2201 Interest of corporation controlled by you
Qian Shenglei	2101 Beneficial owner
Zhang Jiang	2201 Interest of corporation controlled by you
Yang Fang	2202 Interest of your spouse
Zhou Ling	2101 Beneficial owner

New Ray Medicine International Holding (HKSE:06108) Headlines

No Headlines